Regen BioPharma, Inc.

OTCPK:RGBP.P Stock Report

Market Cap: US$788.7k

Regen BioPharma Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

David Koos

Chief executive officer

US$10.1k

Total compensation

CEO salary percentage100.0%
CEO tenure3.8yrs
CEO ownership0.009%
Management average tenureno data
Board average tenure9.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has David Koos's remuneration changed compared to Regen BioPharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$867k

Jun 30 2024n/an/a

-US$883k

Mar 31 2024n/an/a

-US$840k

Dec 31 2023n/an/a

-US$775k

Sep 30 2023US$10kUS$10k

US$1m

Jun 30 2023n/an/a

US$1m

Mar 31 2023n/an/a

US$62m

Dec 31 2022n/an/a

US$1m

Sep 30 2022n/an/a

US$2m

Jun 30 2022n/an/a

US$910k

Mar 31 2022n/an/a

-US$67m

Dec 31 2021n/an/a

-US$6m

Sep 30 2021US$1n/a

-US$7m

Jun 30 2021n/an/a

-US$4m

Mar 31 2021n/an/a

US$6m

Dec 31 2020n/an/a

US$2m

Sep 30 2020n/an/a

US$3m

Jun 30 2020n/an/a

US$4m

Mar 31 2020n/an/a

-US$4m

Dec 31 2019n/an/a

-US$454k

Sep 30 2019US$54kUS$54k

-US$3m

Jun 30 2019n/an/a

-US$5m

Mar 31 2019n/an/a

-US$887k

Dec 31 2018n/an/a

-US$2m

Sep 30 2018US$180kUS$180k

-US$5m

Compensation vs Market: David's total compensation ($USD10.05K) is below average for companies of similar size in the US market ($USD653.16K).

Compensation vs Earnings: David's compensation has increased whilst the company is unprofitable.

CEO

David Koos (63 yo)

3.8yrs

Tenure

US$10,050

Compensation

Dr. David Raymond Koos, Ph D., DBA., served as Chairman of the Board of Directors, Chief Executive Officer, President, Secretary and Treasurer at SYBLEU INC. Dr. Koos serves as Chairman, CEO, President, Se...

Board Members

NamePositionTenureCompensationOwnership
David Koos
Chairman3.8yrsUS$10.05k0.0095%
$ 74.7
Amit Patel
Member of Scientific Advisory Board10.2yrsno datano data
Ravinder Reddy
Member of Scientific Advisory Board2yrsno datano data
Weiping Min
Member of Scientific Advisory Board12.6yrsno datano data
David Suhy
Member of Scientific Advisory Board11.3yrsno datano data
Santosh Kesari
Member of Scientific Advisory Board9.4yrsno datano data
Hinrich Gronemeyer
Member of Scientific Advisory Board9.5yrsno datano data
William Blaner
Member of Scientific Advisory Board9.5yrsno datano data
Rohit Duggal
Member of Scientific Advisory Board9.4yrsno datano data
Jonathan Baell
Member of Scientific Advisory Board9.3yrsno datano data
Stefano Bertuzzi
Member of Scientific Advisory Board9.2yrsno datano data
Mohammad Haris
Member of Scientific Advisory Board2yrsno datano data

9.4yrs

Average Tenure

Experienced Board: RGBP.P's board of directors are considered experienced (9.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 10:16
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Regen BioPharma, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution